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Investigation of the Chromosome 17q25 PSORS2
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Nilesh Morar1, Anne M. Bowcock2, John I. Harper3, William O.C.M. Cookson1 and Miriam F. Moffatt1
Psoriasis and atopic dermatitis (AD) are strongly genetic and inherited as multi-factorial traits. In both diseases,
linkage has been reported to chromosome 17q25. For psoriasis, the locus has been labelled PSORS2. Two peaks
of association here contain the psoriasis candidate genes SLC9A3R (solute carrier family 9, isoform 3 regulatory
factor), NAT9 (N-acetyltransferase superfamily), and RAPTOR (rapamycin (TOR)). We genotyped 14 of the most
significantly associated single-nucleotide polymorphisms (SNPs) in these genes in a panel of 148 families (ECZ1)
identified through a proband with active AD. The panel contains 350 siblings and 245 sib-pairs. Replication of
positive findings was sought in a second panel, MRC-E, comprising of 278 families, 634 siblings, and 470 sib-
pairs. SNP genotyping was carried out by Sequenom MassArray technology. Using family-based tests of
association (transmission disequilibrium test), rs878906, in intron 3 of NAT9, was significantly associated with AD
(P¼ 0.010) in the ECZ1 panel. In the MRC-E panel, rs895691, between the end of exon 6 of SLC9A3R1 and exon 7
of NAT9, was associated with AD (P¼ 0.037). These were not significant when multiple comparisons were taken
into account. Haplotype analysis revealed no significant associations in either population. These results suggest
that the psoriasis candidate genes do not account for previously observed linkage of the 17q25 PSORS2 locus to AD.
Journal of Investigative Dermatology (2006) 126, 603–606. doi:10.1038/sj.jid.5700108; published online 5 January 2006
INTRODUCTION
Atopic dermatitis (AD) begins in infancy and childhood and is
typified by itchy, inflamed skin. It affects 10–20% of children
in Western societies and is strongly familial. While AD and
psoriasis are clinically and pathologically distinct, both
diseases are characterized by dry, scaly skin and disturbed
epidermal differentiation. A genome screen of AD identified
linkage to AD, or to AD and asthma combined on chromo-
somes 1q21, 17q25, and 20p (Cookson et al., 2001). These
regions correspond closely to known psoriasis loci (Tomfohrde
et al., 1994; Trembath et al., 1997; Capon et al., 2002). The
conservative probability of this overlap occurring by chance
is less than 3 in 100,000 (Cookson et al., 2001). A further AD
locus identified on chromosome 3q21 also corresponds to
a previously reported psoriasis susceptibility locus (Enlund
et al., 1999a; Lee et al., 2000). The co-localization of AD
with psoriasis loci indicates that AD is influenced by genes
with general effects on dermal inflammation and immunity.
Psoriasis is an inflammatory disorder, which is inherited as
a multi-factorial trait. It affects 2% of the European population.
At least nine susceptibility loci have been implicated (Capon
et al., 2002). Chromosome 17q25 harbors a susceptibility
locus for psoriasis (PSORS2) that has been confirmed in
independent family sets (Tomfohrde et al., 1994; Nair et al.,
1997; Enlund et al., 1999b; Zheng et al., 2003). High-density
genetic mapping of the PSORS2 interval in US-based
psoriasis patients showed two peaks of strong association
separated by 6 Mb (Helms et al., 2003). The proximal peak
spans 20 kb and associated single-nucleotide polymorphisms
(SNPs) lie in or near SLC9A3R1 (solute carrier family 9,
isoform 3 regulatory factor 1) and NAT9 (N-acetyltransferase
superfamily) genes. Interestingly, the authors of the study
found that one of the disease-associated SNPs, rs734232,
lying between SLC9A3R1 and NAT9, resulted in the loss of
binding by the runt-related transcription factor RUNX1
binding. The distal peak of association that is 6 Mb away is
in RAPTOR (target of rapamycin (TOR) – scaffold protein
containing WD repeats) (Figure S1).
To determine the relevance of PSORS2 genetic variants in
AD, we genotyped 14 representative SNPs from both
association peaks based on their reported significance of
disease association in two panels of families (Figure S1).
Together, the panels consist of 426 families containing 984
siblings and 715 sib-pairs.
RESULTS
In the ECZ1 panel, 53% of the children had physician-
diagnosed AD, whereas 37% had asthma. Forty-six percent of
children in the MRC-E panel had AD and 36% had asthma.
Ninety-nine percent of the children were under 5 years of
age. Of the 14 SNPs genotyped in the ECZ1 panel, a single
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SNP, rs878906 situated in the NAT9 gene, showed nominally
significant association with AD (P¼ 0.010). This association,
however, did not show replication in the MRC-E panel but
instead a weak association (P¼0.037) with AD was seen for
the SNP rs895691 located between the end of exon 6 of
SLC9A3R1 and the start of exon 7 of the NAT9 gene (Table 1).
Neither of these associations remained significant when
multiple comparisons were taken into account using the
Bonferroni correction. None of the other phenotypes
examined were associated with any of the SNPs. All children
were recruited from a tertiary hospital and had severe AD;
hence, stratification analysis based on severity of AD was not
performed.
Four common haplotypes accounted for the haplotype
diversity in the ECZ1 (80.9%) and the MRC-E (78.3%) panels.
These were 1.1.1.2.2.1.2.2.2.2.1, 2.2.2.1.1.2.1.1.1.1.2,
1.2.1.1.2.1.1.1.2.1.2, and 1.1.1.2.2.1.2.2.2.1.1. Other haplo-
types accounted for less than 2% of the haplotype diversity in
both panels. Analysis of 11 marker haplotypes in the
proximal peak of association did not show significant
association in either population. The markers were in partial
linkage disequilibrium (Figure S2).
The combined panel would provide approximately 80%
power to detect a genotype relative risk of 2.5 under a
dominant model with a type one error rate of 0.05 assuming a
D0 of 0.9 between the marker and the disease allele (Sham
et al., 2000). The magnitude of this genetic effect only refers
to AD and cannot be compared to the strength of the genetic
effect attributed to this locus in psoriasis as the effect size has
not been published for the SLC9AR1, NAT 9, and RAPTOR
region in psoriasis.
DISCUSSION
This is the first study examining the association of suscept-
ibility variants in the PSORS2 psoriasis locus and childhood
AD since the initial genome screen showed coincident
regions of linkage in these two diseases (Cookson et al.,
2001). Our results suggest that the psoriasis-associated genes
do not account for the linkage seen for AD to the
chromosome 17q25 region.
Eight representative SNPs from both association peaks
were analyzed in a UK data set of psoriatics (Capon et al.,
2004). While there was no evidence for association with the
SLC9AR1/NAT9 variants, there was association between
familial psoriasis and RAPTOR SNPs when restriction
analysis was performed in a subset of patients with a well-
documented family history of psoriasis.
SLC9AR1 is found in keratinocytes within the granular
layer of the epidermis in normal skin and in T-cells and has
been implicated in diverse aspects of epithelial membrane
biology and immune synapse formation in T-cells. A disease-
causing SNP lying between SLC9A3R1 and NAT9 results in
the loss of a RUNX 1 binding site. Loss of RUNX1 binding has
been shown to be associated with susceptibility to auto-
immune diseases such as systemic lupus erythematosus
(Prokunina et al., 2002). NAT9 is also found in keratinocytes
and T-cells and may play a role in glycosylation.
Although the disease-causing variant proposed by Helms
et al. (2003) was strongly associated in their family-based
psoriasis cohort, the SLC9AR1 and NAT9 haplotype confers
only a moderate increase in psoriasis susceptibility with a low
relative risk and interactions with other genes are probably
required for disease to occur (Helms et al., 2003).There is
also considerable genetic heterogeneity of both psoriasis and
AD. This is a possible explanation for the absent association
of these genes with AD in our study. A German study did not
find genetic association of the disease-causing SNP in their
psoriatics (Huffmeier et al., 2005). There was also no
evidence of association of the RUNX1 binding site and
RAPTOR locus with psoriasis despite adequate power and
evidence for linkage of psoriasis to distal chromosome 17q in
families recruited from Germany and the United States (Stuart
et al., 2005). Recently, there was no significant allelic
association between the RUNX1 polymorphism and AD in
a small Japanese adult cohort (Hosomi et al., 2005).
Other candidate genes that map to the same psoriasis and
AD linkages in 17q25 include the EVER1 and EVER2 genes
that predispose to epidermodysplasia verruciformis charac-
terized by life-long human papillomavirus infections (Ramoz
et al., 2002). A shared mechanism between epidermodys-
plasia verruciformis and AD or psoriasis is not immediately
obvious, unless perhaps AD and psoriasis result from chronic
infections with as yet unrecognized organisms.
As genetic linkage is imprecise and several genes are
present under the peak of linkage, more fine mapping studies
are required to identify the AD susceptibility gene(s) on
chromosome 17q25.
Table 1. TDT results for AD in the two panels of
families, ECZ1 and MRC-E
ECZ1 MRC-E
Position no.1 Marker name T NT P-value T NT P-value
73,227,956 rs745318 88 91 0.823 149 177 0.121
73,229,373 rs7420 88 95 0.604 137 144 0.676
73,229,889 rs734232 76 76 1 149 177 0.121
73,230,410 rs895692 93 103 0.479 147 135 0.475
73,230,458 rs895691 94 89 0.712 181 150 0.037
73,231,151 rs12797 74 79 0.686 151 173 0.222
73,231,593 rs880827 92 95 0.826 141 129 0.465
73,231,723 rs3744208 75 78 0.808 99 85 0.302
73,233,128 rs2305214 89 80 0.489 143 124 0.245
73,233,492 rs878906 59 34 0.010 123 112 0.829
73,233,852 rs878907 104 99 0.726 137 150 0.443
79,204,2542 rs1564864 77 67 0.405 84 88 0.760
79,216,5532 rs2019154 71 72 0.934 136 140 0.810
99,230,8022 rs869190 70 73 0.802 88 83 0.702
NT=number of untransmitted alleles; T=number of transmitted alleles;
TDT=transmission disequilibrium test.
1Marker position according to Helms et al. (2003).
2SNPs in the distal peak of association.
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MATERIALS AND METHODS
Families were recruited from the Dermatology clinics at the Great
Ormond Street Hospital for Children, through a child or children
with active AD. A physician-administered questionnaire was
administered for each individual. The questionnaire included the
modified Hanifin and Rajka diagnostic criteria for AD defined by the
UK Working party (Williams et al., 1994a, b). Each family was
examined for evidence of AD by a physician. Unaffected children
were classified as unaffected. The severity of eczema was assessed
using the scoring system of Rajka and Langeland, which categorizes
patients into mild (3.0 –4.0), moderate (4.5 –7.5), or severe (8.0 –9.0)
disease on the basis of surface area involvement, continuity of
disease, and nocturnal pruritus (Rajka and Langeland, 1989). The
total serum IgE concentration was measured by a fluorescent enzyme
immunoassay (Pharmacia CAP system, Pharmacia, Uppsala, Sweden).
Initially, a panel of 148 nuclear families of northern European
origin were examined, the ECZ1 panel. ECZ1 has 350 siblings and
245 sib-pairs. The same families had been used previously in an AD
genome screen (Cookson et al., 2001). Replication was sought in the
MRC-E eczema panel comprising of 278 families, 634 siblings, and
470 sib-pairs. Approval for the studies was obtained through the
University of Oxford and Great Ormond Street Hospital for Sick
Children Ethics Committees. Participants gave their written informed
consent. The investigations were conducted according to the
Declaration of Helsinki Principles.
DNA for all individuals was extracted using standard techniques
and then an aliquot was used as a template for whole-genome
amplification by primer extension PCR (Zhang et al., 1992). We
genotyped 14 of the previously reported (Helms et al., 2003)
psoriasis-associated SNPs in the SLC9A3R, NAT9, and RAPTOR
genes. Eleven markers were chosen from the proximal and three
from the distal peaks of association (Supplementary Figure S1). SNP
genotyping was performed using Sequenom MassArray technology
(Sequenom Inc., San Diego, CA). Family-based association analysis
was carried out using the transmission disequilibrium test and
quantitative transmission disequilibrium test to examine the trans-
mission rates of marker alleles for the phenotypes AD and log IgE.
Haplotypes were generated by Multipoint Engine for Rapid Like-
lihood Inference (Abecasis et al., 2000) and after recoding as
individual alleles, examined for association with AD with transmis-
sion disequilibrium test.
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SUPPLEMENTARY MATERIAL
Figure S1. Relative positions of the SNPs in the chromosome 17q25 PSORS2
locus (not to scale). Location of genes according to Ensembl v33 Sept 2005 –
SLC9A3R1: 70256363–70277084; NAT9: 70284095–70278283; RAPTOR:
76133663–76554766. Genetic linkage to psoriasis susceptibility was origin-
ally reported to be just proximal to D17S1301 (position: 70192530–
70192683) (Speckman et al., 2003). Subsequent genotyping resulted in
two peaks of association being seen – a proximal peak lying 80 kb distal to
D17S1301 and containing the SLC9A3R1 and NAT9 genes and a distal peak
lying 6 Mb within intron 3 of the RAPTOR gene (Helms et al., 2003). The two
markers reported to show linkage to atopic dermatitis in the genome screen of
Cookson et al. (1996) are also shown. D17S784 (position: 75416786–
75417019) and D17S928 (position: 77846169–77846317).
Figure S2. Linkage disequilibrium (LD) between chromosome 17q25 PSORS2
polymorphisms. The marker positions are shown across the diagonal of the
figure. Pairwise estimations of D0 are shown on a scale from 0.98 (complete
LD: red) to 0.84. Marker positions are shown as a schematic rather than actual
distances apart.
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